公开(公告)号：US20140235833A1

公开(公告)日：2014-08-21

申请号：US14265416

申请日：2014-04-30

Applicant: Fujita Health University

Inventor： Atsushi SUGIOKA ,  Gene KUROSAWA ,  Mariko SUMITOMO ,  Yoshikazu KUROSAWA

IPC: C07K16/30

CPC classification number: C07K16/30 ,  C07K16/005 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/303 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C12N15/1138 ,  C12N2310/14 ,  G01N33/57492 ,  G01N33/6854

Abstract: The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies. The invention further relates to transformants comprising said nucleic acids or vectors.

Abstract translation: 本发明涉及针对HER1的分离抗体，针对CD147的分离抗体，针对CD73的分离抗体和针对EpCAM的分离抗体; 包括所述抗体的试剂和组合物; 和所述试剂，组合物和抗体的用途。 本发明还涉及表达所述抗体的核酸和载体。 本发明还涉及包含所述核酸或载体的转化体。

公开(公告)号：US10169845B2

公开(公告)日：2019-01-01

申请号：US14574614

申请日：2014-12-18

Applicant: Toshiba Medical Systems Corporation ,  Fujita Health University

Inventor： Takuya Sakaguchi ,  Takashi Ichihara

IPC: G06K9/00 ,  G06T5/00 ,  A61B6/00

Abstract: According to one embodiment, a medical image processing apparatus includes an image acquisition part and a data processing part. The image acquisition part is configured to obtain X-ray image data of an object including not less than three phantoms whose X-ray absorption factors are different from each other. The data processing part is configured to generate corrected X-ray image data of the object by correcting the obtained X-ray image data or other X-ray image data. The obtained X-ray image data or the other X-ray image data are corrected using a nonlinear function obtained based on pixel values of the obtained X-ray image data. The pixel values correspond to the phantoms.

公开(公告)号：US10030071B2

公开(公告)日：2018-07-24

申请号：US14916943

申请日：2014-09-05

Applicant: UNIVERSITY OF MIYAZAKI ,  FUJITA HEALTH UNIVERSITY ,  PERSEUS PROTEOMICS INC.

Inventor： Kazuhiro Morishita ,  Kazuko Kaneda ,  Yoshikazu Kurosawa ,  Gene Kurosawa ,  Katsuyuki Mitomo ,  Katsushi Kouda ,  Yoshinori Ukai

IPC: A61K39/395 ,  C07K16/00 ,  C07K16/46 ,  C07K16/28 ,  A61K31/365 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/00

Abstract: It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.

公开(公告)号：US20160194400A1

公开(公告)日：2016-07-07

申请号：US14916943

申请日：2014-09-05

Applicant: UNIVERSITY OF MIYAZAKI ,  FUJITA HEALTH UNIVERSITY ,  PERSEUS PROTEOMICS INC.

Inventor： Kazuhiro MORISHITA ,  Kazuko KANEDA ,  Yoshikazu KUROSAWA ,  Gene KUROSAWA ,  Katsuyuki MITOMO ,  Katsushi KOUDA ,  Yoshinori UKAI

IPC: C07K16/28 ,  A61K31/365 ,  A61K31/704 ,  A61K39/395 ,  A61K31/7068

CPC classification number: C07K16/2839 ,  A61K31/365 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  C12N2510/02 ,  A61K2300/00

Abstract: It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.

Abstract translation: 本发明的目的是提供一种抗ITGA6 / B4人抗体，其特异性地识别在细胞膜上表达的ITGA6B4复合物并且抑制ITGA6B4复合物与层粘连蛋白的粘附，以便抑制癌细胞对 也能够显着提高抗癌剂对抗癌剂抗性菌株的效果。 本发明提供抗整联蛋白A6B4的抗体，其中所述抗体特异性识别人整联蛋白A6B4复合物并抑制细胞间粘附。

公开(公告)号：US20140004536A1

公开(公告)日：2014-01-02

申请号：US13891652

申请日：2013-05-10

Applicant: PERSEUS PROTEOMICS INC. ,  FUJITA HEALTH UNIVERSITY

Inventor： Yoshikazu KUROSAWA ,  Maiko KUROSAWA ,  Gene KUROSAWA

IPC: C07K16/30 ,  G01N33/68

CPC classification number: C07K16/30 ,  C07K16/28 ,  C07K2317/622 ,  G01N33/6893

Abstract: To provide a method for detecting cellular DNA damage by specifically recognizing molecules responsive to DNA strand breaks. A method for detecting DNA damage in cells, which comprises administering in vivo, to cells, an antibody against a cell membrane surface antigen that is expressed in cells undergoing DNA strand breaks to a greater extent than in cells not undergoing DNA strand breaks in an environment that causes DNA damage, and analyzing the expression status of the cell membrane surface antigen.

Abstract translation: 提供通过特异性识别对DNA链断裂有反应的分子来检测细胞DNA损伤的方法。 一种用于检测细胞中DNA损伤的方法，其包括在体内向细胞施用针对细胞膜表面抗原的抗体，其在经历DNA链断裂的细胞中表达的程度大于在环境中不经历DNA链断裂的细胞中 导致DNA损伤，并分析细胞膜表面抗原的表达状态。

公开(公告)号：US20250164463A1

公开(公告)日：2025-05-22

申请号：US18838384

申请日：2022-11-30

Applicant: Fujita Health University

Inventor： Kazuo KUNISAWA ,  Akihiro MOURI ,  Toshitaka NABESHIMA

IPC: A61P25/32 ,  G01N33/50

Abstract: Provided are a novel therapeutic agent for a mental disorder and a screening method for a therapeutic agent for a mental disorder. The therapeutic agent for a mental disorder includes clemastine or a pharmacologically acceptable salt thereof as an active ingredient. According to the therapeutic agent of the present invention, myelin sheath abnormality and brain dysfunction due to a mental disorder can be mitigated. Further, through use of the screening method of the present invention, a therapeutic agent for a mental disorder can be screened for.

公开(公告)号：US09605053B2

公开(公告)日：2017-03-28

申请号：US15017246

申请日：2016-02-05

Applicant: Fujita Health University ,  The Research Foundation for Microbial Diseases of Osaka University

Inventor： Yoshikazu Kurosawa ,  Yoshitaka Iba ,  Nobuko Ohshima ,  Yoshinobu Okuno

IPC: A61K39/395 ,  A61K39/42 ,  A61K39/00 ,  A61P31/16 ,  C07K16/18 ,  C07K16/10

CPC classification number: C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2319/00

Abstract: Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody.

公开(公告)号：US20160200799A1

公开(公告)日：2016-07-14

申请号：US14913613

申请日：2014-08-20

Applicant: FUJITA HEALTH UNIVERSITY ,  THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY ,  PERSEUS PROTEOMICS INC.

Inventor： Yoshikazu KUROSAWA ,  Nobuko OSHIMA ,  Yoshinobu OKUNO ,  Katsuyuki MITOMO ,  Katsushi KOUDA

IPC: C07K16/10

CPC classification number: C07K16/1018 ,  C07K2317/76

Abstract: It is an object of the present invention to provide a novel antibody having a high binding activity and a high neutralizing activity on influenza viruses. The present invention provides an antibody, which neutralizes H1 influenza virus and/or H5 influenza virus, wherein the antibody has a heavy chain variable region having CDRs consisting of a defined heavy chain first complementarity-determining region (VH CDR1), a defined heavy chain second complementarity-determining region (VH CDR2) and a defined heavy chain third complementarity-determining region (VH CDR3), and a light chain variable region having CDRs consisting of a defined light chain second complementarity-determining region (VL CDR2) and a defined light chain third complementarity-determining region (VL CDR3).

Abstract translation: 本发明的目的是提供一种对流感病毒具有高结合活性和高中和活性的新型抗体。 本发明提供中和H1流感病毒和/或H5流感病毒的抗体，其中该抗体具有由定义的重链第一互补决定区（VH CDR1）构成的CDR的重链可变区，定义的重链 第二互补决定区（VH CDR2）和定义的重链第三互补决定区（VH CDR3）和轻链可变区，其具有由定义的轻链第二互补决定区（VL CDR2）和定义的 轻链第三互补决定区（VL CDR3）。

公开(公告)号：US08965085B2

公开(公告)日：2015-02-24

申请号：US13886910

申请日：2013-05-03

Applicant: Toshiba Medical Systems Corporation ,  Fujita Health University ,  The Johns Hopkins University

Inventor： Takuya Sakaguchi ,  Takashi Ichihara ,  Jingwu Yao ,  Richard T. George ,  Jeff Trost ,  Omair Khwaja Yousuf ,  Joao A. C. Lima

IPC: G06K9/00 ,  G06T7/00 ,  A61B6/00

CPC classification number: G06T7/0012 ,  A61B6/4441 ,  A61B6/481 ,  A61B6/486 ,  A61B6/503 ,  A61B6/504 ,  A61B6/5258

Abstract: An image processing apparatus according to the present embodiment includes a correcting unit. The correcting unit identifies, based on an observation value of a residual contrast material component that is injected to a subject before a predetermined timing and remains in the subject, the residual contrast material component and a new contrast material component that is newly injected to the subject after the predetermined timing regarding a contrast material component that is included in an image, and corrects an observation value of the contrast material component included in the image.

Abstract translation: 根据本实施例的图像处理装置包括校正单元。 校正单元基于在预定时间之前注入到被检体的残留造影材料成分的观察值，并且保留在被检体内，残留对象物质成分和新注射到被检体的新造影剂成分 在关于包括在图像中的对比度材料分量的预定定时之后，并且校正包括在图像中的对比度材料分量的观察值。

公开(公告)号：US20160202265A1

公开(公告)日：2016-07-14

申请号：US14913879

申请日：2014-08-18

Applicant: Fujita Health University

Inventor： Yoshikazu Kurosawa ,  Nobuko Ohshima

IPC: G01N33/68 ,  C07K16/10

CPC classification number: G01N33/686 ,  C07K16/1018 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/56983 ,  G01N2333/11

Abstract: Provided is a method of providing an effective means as a countermeasure for handling a pandemic of an influenza virus. The resistance to a type A influenza virus is determined using, as an indicator, the presence or otherwise of antibodies using the VH1-69 gene in a biological sample originating from a subject.

Abstract translation: 提供了一种提供有效手段作为处理流感病毒大流行的对策的方法。 作为来自受试者的生物样品中使用VH1-69基因的抗体的存在或以其他方式作为指标来确定对A型流感病毒的抗性。